miRNA-506 Affects Metastasis, Angiogenesis in Gastric Cancer

This article originally appeared here.
Share this content:
miRNA-506 Affects Metastasis, Angiogenesis in Gastric Cancer
miRNA-506 Affects Metastasis, Angiogenesis in Gastric Cancer

TUESDAY, Sept. 15, 2015 (HealthDay News) -- MiRNA-506 (miR-506) is involved in gastric cancer, inhibiting the epithelial-to-mesenchymal transition and suppressing angiogenesis, according to a study published online Sept. 8 in The American Journal of Pathology.

Zhen Li, from the Cancer Research Institute of Southern Medical University in China, and colleagues examined the possible role of miR-506 in gastric cancer, assessed its correlations with clinical outcomes, and investigated its potential role in angiogenesis and metastasis of gastric cancer cells.

The researchers found that miR-506 expression was a useful marker for stratifying patients from early to advanced clinical stages and for prediction of overall survival. Overexpression and depletion, respectively, of miR-506 inhibited and promoted the epithelial-to-mesenchymal transition of gastric cancer cells. Gastric cancer angiogenesis was suppressed by miR-506, which also was linked to decreased matrix metalloproteinase-9 expression. A target of miR-506, ETS1, was expressed in 71.1 percent of gastric cancer tissue samples. ETS1 expression also correlated with matrix metalloproteinase-9 expression.

"Our study revealed the functional relevance of miR-506 with respect to angiogenesis and metastasis, suggesting that miR-506 acts as a tumor suppressor in gastric cancer," the authors write. "Additional studies will be needed to explore the potential clinical utility of miR-506 as a potential biomarker for gastric cancer prognosis and as a new potential therapeutic target."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »